Table 3.
Model-adjusted risks of GC therapy
| Estimate (95% CI) | ||||||
|---|---|---|---|---|---|---|
| Risk type | Outcome | Model | No early IFN (n = 171) | P-value | With early IFN (n = 203) | P-value |
| Hazard ratio | Hospital discharge | Cox proportional hazardsa | 0.56 (0.39–0.80) | 0.002 | 1.13 (0.81–1.58) | 0.464 |
| Hazard ratio | Symptom relief | Cox proportional hazardsa | 0.65 (0.46–0.93) | 0.018 | 1.15 (0.82–1.60) | 0.416 |
| Odds ratio | Prolonged viral shedding | Logistic regressiona | 3.74 (1.64–8.53) | 0.002 | 0.49 (0.20–1.21) | 0.121 |
GC glucocorticoids, CI confidence interval
aModel adjusted for gender, hypertension, diabetes, oxygen saturation at admission, symptom count at admission, lopinavir/ritonavir, oseltamivir, and umifenovir use. Cox models were fitted to all survivors, and logistic regression were fitted to patients ceased viral shedding before discharge or death